β3-Adrenoceptor Agonist-Induced Increases in Lipolysis, Metabolic Rate, Facial Flushing, and Reflex Tachycardia in Anesthetized Rhesus Monkeys
- Gary J. Hom1,
- Michael J. Forrest1,
- Thomas J. Bach1,
- Edward Brady1,
- Mari Rios Candelore2,
- Margaret A. Cascieri2,
- Donna J. Fletcher1,
- Michael H. Fisher3,
- Susan A. Iliff4,
- Robert Mathvink3,
- Joseph Metzger1,
- Victor Pecore5,
- Richard Saperstein1,
- Thomas Shih3,
- Ann E. Weber3,
- Matthew Wyvratt3,
- Peter Zafian1 and
- D. Euan MacIntyre1
- 1Merck Research Laboratories, Departments of Animal Pharmacology (G.J.H., M.J.F., T.J.B., E.B., D.J.F., J.M., R.S., P.Z., D.E.M.),2Immunology and Rheumatology (M.R.C., M.A.C.), 3Medicinal Chemistry (M.H.F., R.M., T.S., A.E.W., M.W.), 4Comparative Medicine (S.A.I.), and5Statistics (V.P.), Rahway, New Jersey
Abstract
The effects of two β3-adrenergic receptor agonists, (R)-4-[4-(3-cyclopentylpropyl)-4,5-dihydro-5-oxo-1H-tetrazol-1-yl]-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]benzenesulfonamide and (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)- ethyl]amino]ethyl]phenyl]-1-(4-octylthiazol-2-yl)-5-indolinesulfonamide, on indices of metabolic and cardiovascular function were studied in anesthetized rhesus monkeys. Both compounds are potent and specific agonists at human and rhesus β3-adrenergic receptors. Intravenous administration of either compound produced dose-dependent lipolysis, increase in metabolic rate, peripheral vasodilatation, and tachycardia with no effects on mean arterial pressure. The increase in heart rate in response to either compound was biphasic with an initial rapid component coincident with the evoked peripheral vasodilatation and a second more slowly developing phase contemporaneous with the evoked increase in metabolic rate. Because both compounds exhibited weak binding to and activation of rhesus β1-adrenergic receptors in vitro, it was hypothesized that the increase in heart rate may be reflexogenic in origin and proximally mediated via release of endogenous norepinephrine acting at cardiac β1-adrenergic receptors. This hypothesis was confirmed by determining that β3-adrenergic receptor agonist-evoked tachycardia was attenuated in the presence of propranolol and in ganglion-blocked animals, under which conditions there was no reduction in the evoked vasodilatation, lipolysis, or increase in metabolic rate. It is not certain whether the β3-adrenergic receptor-evoked vasodilatation is a direct effect of compounds at β3-adrenergic receptors in the peripheral vasculature or is secondary to the release or generation of an endogenous vasodilator. Peripheral vasodilatation in response to β3-adrenergic receptor agonist administration was not attenuated in animals administered mepyramine, indomethacin, or calcitonin gene-related peptide8-37. These findings are consistent with a direct vasodilator effect of β3-adrenergic receptor agonists.
Footnotes
-
Send reprint requests to: Dr. G. Hom, Merck Research Laboratories, Department of External Scientific Affairs, RY80M-292, P.O. Box 2000, Rahway, NJ 07065. E-mail:Gary_Hom{at}Merck.com
- Abbreviations:
- compound A
- (R)-4-[4-(3-cyclopentylpropyl)-4,5-dihydro-5-oxo-1H-tetrazol-1-yl]-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]benzenesulfonamide
- compound B
- (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-1-(4-octylthiazol-2-yl)-5-indolinesulfonamide
- CGRP
- calcitonin gene-related peptide
- NaNp
- sodium nitroprusside
- PE
- phenylephrine
- CHO
- Chinese hamster ovary
- β3AR
- β3-adrenoceptor
-
- Received September 28, 2000.
- Accepted January 9, 2001.
- The American Society for Pharmacology and Experimental Therapeutics



